ProADM Peptide Assay for Early Shock Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to early identify patients at risk of developing physiological shock states or in need of fluid resuscitation or vasopressor therapy, often initiating treatment too late when the condition is severe, leading to diminished oxygen supply and potential organ dysfunction or death.
Innovation Solution
An in vitro method involving the determination of proADM and its fragments in bodily fluids, such as citrate plasma or whole blood, to correlate levels with the need for fluid resuscitation or vasopressor administration, using specific peptides like Adrenomedullin, Midregional-proAdrenomedullin, and C-terminal Proadrenomedullin, and employing sandwich immunoassays for accurate quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If conventional blood pressure monitoring methods are used, then treatment can be initiated when blood pressure drops, but treatment is started too late when the condition is already severe
Solution Approach 1:
The patent measures proADM levels in bodily fluids to identify patients at risk of developing shock states before actual shock occurs. This preliminary identification allows treatment to be initiated in the pre-shock phase, preventing progression to severe shock and reducing mortality. The method enables early intervention by detecting biochemical markers of impending shock rather than waiting for hemodynamic collapse.
Solution Approach 2:
The patent uses proADM (proadrenomedullin) as a biochemical intermediary marker to detect early physiological changes preceding shock. Instead of directly monitoring hemodynamic parameters that change late in shock, the method measures proADM levels which rise earlier in response to stress and hypoperfusion, serving as an intermediate indicator that triggers preventive treatment before critical deterioration.
2Loss of time
If proADM levels are measured to early identify patients at risk, then treatment can be initiated earlier, but the complexity of the diagnostic method increases
Solution Approach 1:
The patent extracts and measures a specific biochemical marker (proADM) from bodily fluids as a standalone diagnostic indicator. By focusing on this single extracted marker rather than requiring complex multi-parameter monitoring systems, the method simplifies the diagnostic approach while enabling early identification. The extraction of proADM as a specific target allows for targeted, relatively simple immunoassay-based measurement.
Solution Approach 2:
The patent replaces complex mechanical hemodynamic monitoring systems with a biochemical assay approach. Instead of requiring sophisticated pressure sensors, flow meters, and complex data integration systems, the method uses laboratory-based proADM measurement which can be performed with standard immunoassay equipment, reducing mechanical complexity while maintaining diagnostic capability.
3Measurement precision
If proADM and its fragments are measured using sandwich immunoassays, then precise quantification is achieved, but the manufacturing and operational complexity increases
Solution Approach 1:
The patent employs sandwich immunoassays that can measure multiple proADM fragments (full-length proADM, mid-regional proADM, and C-terminal proADM) using a universal assay platform. The same basic immunoassay methodology applies to different proADM forms, allowing precise quantification of various fragments without requiring entirely separate assay systems. This multi-functional approach achieves comprehensive measurement while maintaining operational feasibility through standardized procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early identification of patients at risk, allowing for timely initiation of fluid resuscitation and vasopressor therapy before severe blood pressure decline, potentially reducing mortality and organ dysfunction by using specific peptide thresholds and assays for precise measurement.
Implementation Method 1
employing sandwich immunoassays for accurate quantification
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Subject matter of the present invention is an in vitro method for identifying a subject in need of administration of fluid resuscitation or a vasopressor comprising the following steps: • Determining the level of proADM and/or fragments thereof having at least 6 amino acids in a bodily fluid of said subject • Correlating said level with the need of said patient for fluid resuscitation or administration of a vasopressor wherein said patient is identified as having such a need if the level of proADM and/or fragments thereof having at least 6 amino acids in the bodily fluid of said subject is above a threshold.